Small Pharma Inc. (TSXV: DMT / OTCQB: DMTTF), a biotechnology company focused on short-duration psychedelic-assisted therapies for mental health conditions, today announces an update to its intellectual property (“IP“) portfolio, demonstrating significant progress already made by the Company in 2023.
Small Pharma aims to protect its pipeline programs through a multi-layered IP strategy with four core areas of protection. These areas of protection include: Composition of Matter, covering novel drug substances; Medical Use, covering therapeutic compositions and medical uses thereof; Drug Product, covering pharmaceutical formulations; and Synthetic Route, covering the novel and efficient synthesis of high purity drug substance at scale.
Since the previous IP portfolio update on February 1, 2023, the Company has secured five new granted patents, with three more expected to be granted by May 31, 2023. Additionally, it has received five patent Notices of Allowance. The additional IP covers the four focused areas of protection and multiple markets, strengthening the Company’s international IP position.
The new patent grants and Notices of Allowance are summarized below.
Patent
Protection | Description | Market | Patent No. | Status |
Composition of
Matter
| For certain deuterated homologues of certain tryptamine compounds | USA | 11,578,039 | Granted |
| For certain deuterated homologues of certain tryptamine compounds | New
Zealand | 788543 | Granted |
| For certain deuterated analogues of N,N, dimethyltryptamine (“DMT”) | GB | 2 592 822 | Grant expected
after May 22, 2023 |
| For a group of deuterated homologues of DMT | USA | 11,660,289 | Grant expected on
May 30, 2023 |
| For a group of deuterated homologues of DMT | Europe | 4 031 529 | Notice of
Allowance |
Medical Use
| Of certain deuterated analogues of DMT | GB | 2 586 940 | Grant expected
after May 25, 2023 |
| Medical use and therapeutic compositions of a group of deuterated homologues of DMT | Australia | 2021204158 | Notice of
Allowance |
| Medical use and therapeutic compositions of a group of deuterated homologues of DMT | New Zealand | 794833 | Notice of
Allowance |
| Therapeutic compositions of a group of deuterated homologues of DMT | Japan | 2022-574099 | Notice of
Allowance |
Drug Product
| Novel optimized injectable formulation of DMT based compounds | Australia | 2021334933 | Granted |
| Therapeutic solid dosage forms of deuterated DMT analogues | GB | 2 595 776 | Granted |
Synthetic Route
| Novel efficient synthesis of high purity DMT and deuterated DMT analogues at scale | USA | 11,643,390 | Granted |
| Novel efficient synthesis of high purity DMT and deuterated DMT analogues at scale | Canada | 3160337 | Notice of
Allowance |
As of May 24, 2023, Small Pharma’s IP portfolio consists of 19 granted patents, with 97 allowed or pending. The protection covering each of the Company’s pipeline programs is outlined below.
| Candidate / Project | Relevant Patents in Portfolio
(No. active patents / pending patent applications) |
| SPL0261, SPL0282, SPL0293 | 4 granted patents and 31 allowed and pending applications |
| SPL028 | 6 granted patents, 37 allowed and pending applications |
| SPL028, SPL029 | 8 allowed and pending applications |
| SPL029 | 4 granted patents, 11 allowed and pending applications |
| Non-psychedelic / other | 5 granted patents, 10 allowed and pending applications |
1Intravenous or intramuscular DMT
2 Injectable deuterated DMT series
3 Oral tryptamine series
“Our team has made great progress this year to further strengthen our proprietary IP position in key international markets. We continue to build multi-layered IP protection around each of our pipeline programs, helping to optimize their commercial potential. We are pleased that our efforts to invest in developing novel treatment innovations for patients continues to be recognized in multiple jurisdictions.”
George Tziras, Chief Executive Officer of Small Pharma
About Small Pharma
Small Pharma is a biotechnology company progressing a pipeline of short-duration psychedelic-assisted therapies for the treatment of mental health conditions. The Company’s current focus is on exploring new therapeutic approaches for depression. Small Pharma’s lead candidate, SPL026, is a proprietary synthetic formulation of N, N-dimethyltryptamine. The Company is advancing clinical programs of SPL026 and SPL028 with supportive therapy for the treatment of mental health conditions, and was granted an Innovation Passport designation from the U.K. Medicines and Healthcare products Regulatory Agency for IV SPL026 with supportive therapy for Major Depressive Disorder. In addition, Small Pharma has a pipeline of proprietary preclinical assets in development.